AstraZeneca's $10 billion acquisition proposal for Rhythm Pharmaceuticals and obesity treatment market competition
AZN Astrazeneca plc
$185.48 -0.69%
View chart & analysis → 
- 1AstraZeneca has proposed a $10 billion acquisition amount for Rhythm Pharmaceuticals.
- 2Rhythm Pharmaceuticals recorded $92.1 million in quarterly global IMCIVREE sales.
- 3Palatin Technologies plans to start Phase 1 clinical trials for its key lipid peptide in the first half of 2027.
So what's the key point?
AstraZeneca has proposed to acquire Rhythm Pharmaceuticals for $10 billion. Rhythm Pharmaceuticals is gaining attention as its drug sales reached $92.1 million.
Source FinanceWire · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.